Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises

• Status: Unknown status
• Trial end date: 2019-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the use of ketamine, sniffed in the nose, is a safe and effective way to help reduce pain in pediatric sickle cell patients with pain crises in resource-limited settings.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cameroon Baptist Convention Health
• Collaborators: Carolinas Medical Center; Muhimbili National Hospital
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• Sickle cell disease (SCD)

• Vasoocclusive pain crisis

• Requiring analgesia

Exclusion Criteria:

• Anatomic variations of nose precluding intranasal medication administration

• Ketamine allergy

• Non-verbal

• Obtunded

• Pregnant

• Other acute SCD complications:

• Acute chest syndrome

• Sepsis

• Stroke

• Splenic sequestration

• Pulmonary embolism

• Acute osteomyelitis